Motorsport in Reverse, Despite New Product Launch
Motorsport Games Inc. (NASDAQ: MSGM) shares lost ground Tuesday. The Miami-based company, a racing game developer and publisher, released Le Mans Ultimate Version 1.0, marking the completion of the title’s Early Access phase and ushers in a new era of continued development and expansion for the official game of the FIA World Endurance Championship (WEC) and the 24 Hours of Le Mans.“At the heart of the 1.0 release,” reads this morning’s news release, “are two headline additions - the Aston Martin Valkyrie AMR LMH and the Mercedes AMG LMGT3 now available as part of the base game at no extra cost to players. These cars, recreated with Studio 397’s renowned attention to detail, enhance the grid with world-class performance and stunning visuals, offering players an opportunity to race two of the most exciting entries from the 2025 FIA World Endurance Championship season.” What’s more, the company says, the update includes the BMW M4 Evo LMGT3, revised and brought up to 2025 specifications. It is available for free to owners of the previous M4, available as part of 2024 Pack 3. The addition of 2025 season liveries is also a part of this release, with the new for 2025 car position boards for added immersion.Beyond new vehicles, Version 1.0 brings meaningful refinements to gameplay, simulation and user experience. MSGM shares docked 10 cents, or 2.7%, to start Tuesday at $3.55.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


